Heart failure & cardiomyopathiesRandomised controlled trial
Efficacy and safety of human albumin combined with furosemide in acute decompensated heart failure with hepatic dysfunction
- prospective, open-label, randomized-pragmatic trial
Authors' conclusion
In this hypothesis generating study, among patients with ADHF and hepatic dysfunction, concomitant use of IV albumin and furosemide for the first 72 hours resulted in a significant improvement in subjective perception symptoms of decongestion and a milder increase in creatinine levels than IV furosemide alone.
Study context
- Population
- Patients with hepatic dysfunction hospitalized for acute decompensated heart failure (ADHF)patients recruited (78 years, 54% female)
- Participants
- 241 patients
- Comparison
- Intravenous (IV) albumin with furosemide vs IV furosemide alone
- Primary endpoint
- Coprimary: patients' global assessment of symptoms score (AUC of visual analog scale score) and change in creatinine levels
- Follow-up
- 72 hours from admission
Primary result
As reported in the abstract
| Group | Global assessment of symptoms AUCbaseline-72 h | Increase in creatinine |
|---|---|---|
| IV albumin with furosemide | 3,767 points | 0.07 mg/dL |
| IV furosemide alone | 3,457 points | 0.18 mg/dL |
Further findings
Length of stay
Incidence of worsening renal function
- Length of stay — 1 day shorter in the experimental treatment group
- P < .001
- Incidence of worsening renal function — Lower in the experimental treatment group
- P = .037
Original publication
Efficacy and safety of human albumin combined with furosemide in acute decompensated heart failure with hepatic dysfunction. Am Heart J. Published 3 August 2026. doi:10.1016/j.ahj.2026.107526
Summarised from the published abstract; every number is checked against it